Effects of fasudil in patients with high-altitude pulmonary hypertension

European Respiratory Journal

Volumn 39, Issue 2, 2012, Pages 496-498

  Kojonazarov, B ^a,c   Myrzaakhmatova, A ^b   Sooronbaev, T ^b   Ishizaki, T ^d   Aldashev, A ^a  

^a Institute of Molecular Biology and Medicine   (Kyrgyzstan)

^b National Center of Cardiology and Internal Medicine   (Kyrgyzstan)

^c JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^d UNIVERSITY OF FUKUI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FASUDIL; GUANOSINE TRIPHOSPHATASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ANAMNESIS; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; HIGH ALTITUDE PULMONARY HYPERTENSION; HOT FLUSH; HUMAN; JAPAN; KIDNEY FUNCTION; LETTER; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; XEROSTOMIA;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ACCLIMATIZATION; ALTITUDE SICKNESS; HUMANS; HYPERTENSION, PULMONARY; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84856718633     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00095211     Document Type: Letter

References (11)

1. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
2. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rhokinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 2000; 522: 177-185. (Pubitemid 30068498)
3. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 420: 629-635. (Pubitemid 36764489)
4. Abe K, Shimokawa H, Morikawa K, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004; 94: 385-393. (Pubitemid 38240731)
5. Dahal BK, Kosanovic D, Pamarthi PK, et al. Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. Eur Respir J 2010; 36: 808-818.
6. Mouchaers KT, Schalij I, de Boer MA, et al. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J 2010; 36: 800-807.
7. Oka M, Homma N, Taraseviciene-Stewart L, et al. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007; 100: 923-929. (Pubitemid 46555698)
8. Fukumoto Y, Matoba T, Ito A, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005; 91: 391-392. (Pubitemid 40299237)
9. Ishikura K, Yamada N, Ito M, et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006; 70: 174-178. (Pubitemid 43170128)
10. Abbas AE, Fortuin FD, Schiller NB, et al. A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol 2003; 41: 1021-1027. (Pubitemid 36315548)
11. Fujita H, Fukumoto Y, Saji K, et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 2010; 25: 144-149.